Stem Cell Therapy for Parkinson's Disease
(HBPD04 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing whether special cells from human fat tissue can help treat Parkinson's disease. The study involves patients with Parkinson's who will receive these cells. The goal is to see if these cells can repair or protect brain cells and improve symptoms. These cells have shown promise in animal models for treating Parkinson's disease.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, your Carbidopa/Levodopa dosage must be less than 1200 mg per day, and the total Levodopa equivalent dose must be less than 1400 mg per day.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does require that your Carbidopa/Levodopa dosage is less than 1200 mg per day and the total Levodopa equivalent dose is less than 1400 mg per day.
What safety data exists for stem cell therapy in Parkinson's disease?
The safety data for stem cell therapy in Parkinson's disease includes a case report of a 77-year-old female patient who received 26 infusions of autologous Hope Biosciences adipose-derived mesenchymal stem cells (HB-adMSCs) over two years, which were safely tolerated without any serious adverse events. Additionally, animal studies have shown that mesenchymal stem cells, including adipose-derived ones, have a positive impact on motor function and memory, and protect dopaminergic neurons, suggesting a promising safety profile. However, further research is needed to fully evaluate the safety and efficacy of these therapies in humans.12345
Is stem cell therapy safe for humans with Parkinson's disease?
Is the treatment Allogeneic HB-adMSCs, Placebo a promising treatment for Parkinson's Disease?
Yes, Allogeneic HB-adMSCs, also known as adipose-derived mesenchymal stem cells, show promise as a treatment for Parkinson's Disease. Research indicates that these stem cells can improve motor functions, protect brain cells, and release helpful substances that support brain health. They have been shown to improve symptoms in both human and animal studies, making them a promising option for further exploration.13678
How is the treatment Allogeneic HB-adMSCs for Parkinson's disease different from other treatments?
Allogeneic HB-adMSCs (adipose-derived mesenchymal stem cells) are unique because they use stem cells from fat tissue to potentially replace damaged neurons and release protective factors, offering a novel approach compared to traditional treatments that mainly manage symptoms without addressing neuron loss.13678
What data supports the idea that Stem Cell Therapy for Parkinson's Disease is an effective treatment?
The available research shows that Stem Cell Therapy, specifically using mesenchymal stem cells, has shown promising results in treating Parkinson's Disease. In a case report, a 77-year-old woman with Parkinson's Disease experienced significant improvements in her symptoms after receiving multiple infusions of stem cells over two years. In animal studies, stem cell treatments improved motor functions and protected brain cells that are typically damaged in Parkinson's Disease. These studies suggest that stem cell therapy could be a beneficial treatment option for Parkinson's Disease, although more research is needed to confirm its effectiveness and safety.13689
What data supports the effectiveness of the treatment Allogeneic HB-adMSCs for Parkinson's Disease?
Who Is on the Research Team?
Djamchid Lotfi
Principal Investigator
Hope Biosciences Stem Cell Research Foundation
Are You a Good Fit for This Trial?
This trial is for men and women aged 45-80 with early to moderate Parkinson's disease diagnosed at least 2 years ago. Participants must not have severe disability, active cancer, major psychiatric conditions, or recent stem cell treatments. They should be on a stable dose of Parkinson's medication and willing to use contraception if necessary.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive multiple infusions of allogeneic HB-adMSCs or placebo over a 32-week period
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Allogeneic HB-adMSCs
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hope Biosciences Stem Cell Research Foundation
Lead Sponsor
Hope Biosciences
Industry Sponsor